Geneva, Dec. 23 -- International Clinical Trials Registry received information related to the study (ISRCTN11948182) titled 'Using a mixed probiotic/prebiotic supplement (MBR-01) to help prevent diarrhea in patients taking abemaciclib for early breast cancer' on Dec. 11.
Study Type: Interventional
Study Design:
Allocation: Non-randomized controlled trial
Masking: Open (masking not used)
Control: Active
Assignment: Patients were assigned to the control or intervention group based on their willingness to receive prophylactic MBR-01, a standardized probiotic and prebiotic protocol
Purpose: Supportive care
Primary Sponsor: Azienda Socio Sanitaria Territoriale di Cremona
Condition:
Prevention or symptomatic reduction of abemaciclib-induc...